Ann Rheum Dis:乌帕替尼治疗类风湿性关节炎的安全性

2020-11-11 xiangting MedSci原创

与阿达木单抗相比,乌帕替尼治疗的患者带状疱疹和CPK升高的风险增加。乌帕替尼、甲氨蝶呤或阿达木单抗治疗的患者恶性肿瘤、MACE和VTE的发生率相似。

乌帕替尼是一种高效的、具有口服活性的选择性 Janus 激酶 1 (JAK1) 抑制剂可用于多种自身免疫性疾病的研究。该研究分析了乌帕替尼治疗中重度活动性类风湿关节炎(RA)每日剂量为15mg和30mg的安全性

研究分析汇总使用乌帕替尼治疗类风湿性关节炎5项III期试验的治疗紧急不良事件(TEAEs)和实验室数据。计算了安慰剂(3项试验; 12/14周)甲氨蝶呤(2项试验;平均使用时间:36周)阿达木单抗(1项试验;平均使用时间:42周)乌帕替尼15mg(5项试验;平均使用时间:53周)和乌帕替尼 30mg(4项试验;平均使用时间:59周)的暴露调整事件发生率

3834例患者接受了乌帕替尼治疗,其中15mg(n = 2630)30mg(n = 1204),暴露患者-年4020.1。上呼吸道感染鼻咽炎和尿路感染是乌帕替尼常见的TEAEs。15mg乌帕替尼阿达木单抗的严重感染率相似,但高于甲氨蝶呤。与甲氨蝶呤和阿达木单抗相比,乌帕替尼组的带状疱疹和肌酸磷酸激酶(CPK)升高的发生率更高,而乌帕替尼 30mg的胃肠道穿孔率更高。各组死亡率恶性肿瘤主要不良血管事件(MACE)和静脉血栓栓塞事件(VTE)的发生率相似。

与阿达木单抗相比,乌帕替尼治疗的患者带状疱疹和CPK升高的风险增加。乌帕替尼甲氨蝶呤或阿达木单抗治疗的患者恶性肿瘤MACE和VTE发生率相似。

原始出处:

Stanley B Cohen. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. November 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2013522, encodeId=2aec201352217, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Oct 03 19:59:21 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898640, encodeId=025e89864092, content=<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>、IL-17单抗、IL-6和TNF单抗、以及传统的治疗药物,形成<a href='/topic/show?id=7face61750b' target=_blank style='color:#2F92EE;'>#类风湿性关节炎#</a>的治疗选择,这几类药物的<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a>均不错,至少较传统的治疗药物安全性要好,就疗效,使用便捷性而言,目前还没有定论,应该是IL-17,JAK可能会优于IL-6和TNF了。但是IL-17与JAK又如何比较?包括短期与长期的作用,可能都得比一比了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=256, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=10237, encryptionId=35791023eaf, topicName=JAK抑制剂), TopicDto(id=76175, encryptionId=7face61750b, topicName=类风湿性关节炎), TopicDto(id=45708, encryptionId=b1e545e085e, topicName=安全性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Nov 12 09:55:26 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266250, encodeId=7e011266250f5, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334270, encodeId=627713342e07e, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418836, encodeId=efca1418836e6, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23345, encryptionId=be872334551, topicName=乌帕替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46123431463, createdName=wodejia-dayu, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483702, encodeId=90721483e0280, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898742, encodeId=9685898e426a, content=多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/6ea5abada2334aabb2737efec80d0f14/16a8a75d63a842369f74b14d4c0fcf86.jpg, createdBy=a8555433340, createdName=春江水暖, createdTime=Thu Nov 12 16:46:46 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
    2021-10-03 zhaojie88
  2. [GetPortalCommentsPageByObjectIdResponse(id=2013522, encodeId=2aec201352217, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Oct 03 19:59:21 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898640, encodeId=025e89864092, content=<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>、IL-17单抗、IL-6和TNF单抗、以及传统的治疗药物,形成<a href='/topic/show?id=7face61750b' target=_blank style='color:#2F92EE;'>#类风湿性关节炎#</a>的治疗选择,这几类药物的<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a>均不错,至少较传统的治疗药物安全性要好,就疗效,使用便捷性而言,目前还没有定论,应该是IL-17,JAK可能会优于IL-6和TNF了。但是IL-17与JAK又如何比较?包括短期与长期的作用,可能都得比一比了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=256, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=10237, encryptionId=35791023eaf, topicName=JAK抑制剂), TopicDto(id=76175, encryptionId=7face61750b, topicName=类风湿性关节炎), TopicDto(id=45708, encryptionId=b1e545e085e, topicName=安全性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Nov 12 09:55:26 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266250, encodeId=7e011266250f5, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334270, encodeId=627713342e07e, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418836, encodeId=efca1418836e6, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23345, encryptionId=be872334551, topicName=乌帕替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46123431463, createdName=wodejia-dayu, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483702, encodeId=90721483e0280, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898742, encodeId=9685898e426a, content=多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/6ea5abada2334aabb2737efec80d0f14/16a8a75d63a842369f74b14d4c0fcf86.jpg, createdBy=a8555433340, createdName=春江水暖, createdTime=Thu Nov 12 16:46:46 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
    2020-11-12 lovetcm

    #JAK抑制剂#、IL-17单抗、IL-6和TNF单抗、以及传统的治疗药物,形成#类风湿性关节炎#的治疗选择,这几类药物的#安全性#均不错,至少较传统的治疗药物安全性要好,就疗效,使用便捷性而言,目前还没有定论,应该是IL-17,JAK可能会优于IL-6和TNF了。但是IL-17与JAK又如何比较?包括短期与长期的作用,可能都得比一比了。

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2013522, encodeId=2aec201352217, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Oct 03 19:59:21 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898640, encodeId=025e89864092, content=<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>、IL-17单抗、IL-6和TNF单抗、以及传统的治疗药物,形成<a href='/topic/show?id=7face61750b' target=_blank style='color:#2F92EE;'>#类风湿性关节炎#</a>的治疗选择,这几类药物的<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a>均不错,至少较传统的治疗药物安全性要好,就疗效,使用便捷性而言,目前还没有定论,应该是IL-17,JAK可能会优于IL-6和TNF了。但是IL-17与JAK又如何比较?包括短期与长期的作用,可能都得比一比了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=256, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=10237, encryptionId=35791023eaf, topicName=JAK抑制剂), TopicDto(id=76175, encryptionId=7face61750b, topicName=类风湿性关节炎), TopicDto(id=45708, encryptionId=b1e545e085e, topicName=安全性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Nov 12 09:55:26 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266250, encodeId=7e011266250f5, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334270, encodeId=627713342e07e, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418836, encodeId=efca1418836e6, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23345, encryptionId=be872334551, topicName=乌帕替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46123431463, createdName=wodejia-dayu, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483702, encodeId=90721483e0280, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898742, encodeId=9685898e426a, content=多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/6ea5abada2334aabb2737efec80d0f14/16a8a75d63a842369f74b14d4c0fcf86.jpg, createdBy=a8555433340, createdName=春江水暖, createdTime=Thu Nov 12 16:46:46 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
    2020-11-13 lmm397
  4. [GetPortalCommentsPageByObjectIdResponse(id=2013522, encodeId=2aec201352217, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Oct 03 19:59:21 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898640, encodeId=025e89864092, content=<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>、IL-17单抗、IL-6和TNF单抗、以及传统的治疗药物,形成<a href='/topic/show?id=7face61750b' target=_blank style='color:#2F92EE;'>#类风湿性关节炎#</a>的治疗选择,这几类药物的<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a>均不错,至少较传统的治疗药物安全性要好,就疗效,使用便捷性而言,目前还没有定论,应该是IL-17,JAK可能会优于IL-6和TNF了。但是IL-17与JAK又如何比较?包括短期与长期的作用,可能都得比一比了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=256, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=10237, encryptionId=35791023eaf, topicName=JAK抑制剂), TopicDto(id=76175, encryptionId=7face61750b, topicName=类风湿性关节炎), TopicDto(id=45708, encryptionId=b1e545e085e, topicName=安全性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Nov 12 09:55:26 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266250, encodeId=7e011266250f5, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334270, encodeId=627713342e07e, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418836, encodeId=efca1418836e6, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23345, encryptionId=be872334551, topicName=乌帕替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46123431463, createdName=wodejia-dayu, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483702, encodeId=90721483e0280, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898742, encodeId=9685898e426a, content=多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/6ea5abada2334aabb2737efec80d0f14/16a8a75d63a842369f74b14d4c0fcf86.jpg, createdBy=a8555433340, createdName=春江水暖, createdTime=Thu Nov 12 16:46:46 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2013522, encodeId=2aec201352217, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Oct 03 19:59:21 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898640, encodeId=025e89864092, content=<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>、IL-17单抗、IL-6和TNF单抗、以及传统的治疗药物,形成<a href='/topic/show?id=7face61750b' target=_blank style='color:#2F92EE;'>#类风湿性关节炎#</a>的治疗选择,这几类药物的<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a>均不错,至少较传统的治疗药物安全性要好,就疗效,使用便捷性而言,目前还没有定论,应该是IL-17,JAK可能会优于IL-6和TNF了。但是IL-17与JAK又如何比较?包括短期与长期的作用,可能都得比一比了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=256, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=10237, encryptionId=35791023eaf, topicName=JAK抑制剂), TopicDto(id=76175, encryptionId=7face61750b, topicName=类风湿性关节炎), TopicDto(id=45708, encryptionId=b1e545e085e, topicName=安全性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Nov 12 09:55:26 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266250, encodeId=7e011266250f5, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334270, encodeId=627713342e07e, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418836, encodeId=efca1418836e6, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23345, encryptionId=be872334551, topicName=乌帕替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46123431463, createdName=wodejia-dayu, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483702, encodeId=90721483e0280, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898742, encodeId=9685898e426a, content=多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/6ea5abada2334aabb2737efec80d0f14/16a8a75d63a842369f74b14d4c0fcf86.jpg, createdBy=a8555433340, createdName=春江水暖, createdTime=Thu Nov 12 16:46:46 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2013522, encodeId=2aec201352217, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Oct 03 19:59:21 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898640, encodeId=025e89864092, content=<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>、IL-17单抗、IL-6和TNF单抗、以及传统的治疗药物,形成<a href='/topic/show?id=7face61750b' target=_blank style='color:#2F92EE;'>#类风湿性关节炎#</a>的治疗选择,这几类药物的<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a>均不错,至少较传统的治疗药物安全性要好,就疗效,使用便捷性而言,目前还没有定论,应该是IL-17,JAK可能会优于IL-6和TNF了。但是IL-17与JAK又如何比较?包括短期与长期的作用,可能都得比一比了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=256, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=10237, encryptionId=35791023eaf, topicName=JAK抑制剂), TopicDto(id=76175, encryptionId=7face61750b, topicName=类风湿性关节炎), TopicDto(id=45708, encryptionId=b1e545e085e, topicName=安全性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Nov 12 09:55:26 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266250, encodeId=7e011266250f5, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334270, encodeId=627713342e07e, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418836, encodeId=efca1418836e6, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23345, encryptionId=be872334551, topicName=乌帕替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46123431463, createdName=wodejia-dayu, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483702, encodeId=90721483e0280, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898742, encodeId=9685898e426a, content=多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/6ea5abada2334aabb2737efec80d0f14/16a8a75d63a842369f74b14d4c0fcf86.jpg, createdBy=a8555433340, createdName=春江水暖, createdTime=Thu Nov 12 16:46:46 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2013522, encodeId=2aec201352217, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Oct 03 19:59:21 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898640, encodeId=025e89864092, content=<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>、IL-17单抗、IL-6和TNF单抗、以及传统的治疗药物,形成<a href='/topic/show?id=7face61750b' target=_blank style='color:#2F92EE;'>#类风湿性关节炎#</a>的治疗选择,这几类药物的<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a>均不错,至少较传统的治疗药物安全性要好,就疗效,使用便捷性而言,目前还没有定论,应该是IL-17,JAK可能会优于IL-6和TNF了。但是IL-17与JAK又如何比较?包括短期与长期的作用,可能都得比一比了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=256, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=10237, encryptionId=35791023eaf, topicName=JAK抑制剂), TopicDto(id=76175, encryptionId=7face61750b, topicName=类风湿性关节炎), TopicDto(id=45708, encryptionId=b1e545e085e, topicName=安全性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Nov 12 09:55:26 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1266250, encodeId=7e011266250f5, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334270, encodeId=627713342e07e, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76164, encryptionId=5306e6164b6, topicName=类风湿)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418836, encodeId=efca1418836e6, content=<a href='/topic/show?id=be872334551' target=_blank style='color:#2F92EE;'>#乌帕替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23345, encryptionId=be872334551, topicName=乌帕替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46123431463, createdName=wodejia-dayu, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483702, encodeId=90721483e0280, content=<a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100826, encryptionId=55a6100826cc, topicName=风湿性关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c237911872, createdName=ms1467340776200723, createdTime=Fri Nov 13 11:59:21 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898742, encodeId=9685898e426a, content=多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/6ea5abada2334aabb2737efec80d0f14/16a8a75d63a842369f74b14d4c0fcf86.jpg, createdBy=a8555433340, createdName=春江水暖, createdTime=Thu Nov 12 16:46:46 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
    2020-11-12 春江水暖

    多学习

    0

相关资讯

JACC:美国超500万患者研究显示,近10%的PCI用于治疗支架内再狭窄

经皮冠状动脉介入治疗(PCI)是目前冠心病治疗的主要手段之一,极大改善了冠心病患者的预后,但介入治疗后再狭窄一直是其无法摆脱的梦魇。

JAMA:发表武汉生物新冠灭活疫苗1/2期试验结果,免疫原性和安全性良好

JAMA发表了联合研制、多家机构共同参与的新冠灭活疫苗1/2期临床试验中期结果,初步表明该疫苗具有良好的免疫原性和安全性,并在讨论中结合其他已发表疫苗结果进行了简要分析。

紫外线灯:用好是防疫利器,用不好是安全隐患

自新冠肺炎疫情暴发以来,前有误饮消毒液住院,后有戴口罩跑步猝死,现有紫外线灯照射损伤。各类防护用品、消毒用品本应为防控疫情、保护健康服务,现在却频频爆出致伤致病的案例。

Int Arch Allergy Immunol:过敏性鼻炎儿童特异性舌下免疫治疗安全性的风险因素研究

良好的依从性往往归因于舌下免疫疗法(SLIT)的良好疗效和安全性。然而,很少有关于儿童SLIT治疗安全性的研究。

Diabetes Obes Metab:老年2型糖尿病患者埃格列净治疗的疗效和安全性

埃格列净改善了T2DM年轻患者和老年患者的血糖控制、BW和SBP,且两组均有较好的耐受性。

Nat Biotechnol:通过代谢工程为细胞疗法提供一种新型的安全关闭开关

在这篇论文中,与斯坦福大学医学院的研究人员合作,展示了为为各种类型的细胞疗法开发出一种新型的安全“关闭”开关,当观察到严重的副作用时,利用这种安全开关就可能让医生减轻这些副作用。